Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC (RAIC)
Rectal Artery Infusion Chemotherapy of Oxaliplatin Plus Capecitabine Combined With Anti-PD1 Antibody After Induction Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer：a Prospective Single-arm Phase II Study
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This PHASE2 trial investigates Rectal Neoplasms and is currently ongoing. Second Affiliated Hospital, School of Medicine, Zhejiang University leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
May 2025 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jul 2023 — Nov 2023 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Mar 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Jun 2022 — Mar 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Second Affiliated Hospital, School of Medicine, Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .